RET and neoplasm: Demonstrated analytical and clinical performance of F1CDx led to the pan-tumor approvals from the U.S. Food and Drug Administration (FDA) in 2023 and the Japan Ministry of Health, Labour and Welfare (MHLW) in 2024 of F1CDx to identify <i>RET</i> fusions in solid tumor patients for treatment with selpercatinib.<h4>Conclusions</h4>F1CDx is an accurate, reliable, FDA- and MHLW-approved method for the pan-tumor identification of <i>RET</i> fusions for treatment with selpercatinib.